Onderneming Inhibikase Therapeutics, Inc.
Aandelen
IKT
US45719W2052
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,4 USD | -2,10% |
|
-0,71% | +10,24% |
Vakgebied
Aantal werknemers: 9
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Protein Kinase Inhibitor Therapeutics
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +111,03% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | 100,0 % | 0 | 100,0 % | +111,03% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Milton Werner
FOU | Founder | 61 | 01-09-08 |
C. Warren Olanow
CTO | Chief Tech/Sci/R&D Officer | - | 04-01-21 |
Dan Williams
AUD | Comptroller/Controller/Auditor | - | - |
Surendra Singh
PRN | Corporate Officer/Principal | - | 01-08-14 |
W. Roger Rush
PRN | Corporate Officer/Principal | - | 01-01-15 |
General Counsel | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dennis Berman
BRD | Director/Board Member | 73 | 01-09-19 |
Paul Grint
BRD | Director/Board Member | 66 | 22-12-20 |
Milton Werner
FOU | Founder | 61 | 01-09-08 |
Gisele Dion
BRD | Director/Board Member | 57 | 01-09-22 |
Roy Freeman
BRD | Director/Board Member | 72 | 22-12-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 7 216 145 | 6 318 888 ( 87,57 %) | 0 | 87,57 % |
Bedrijfsgegevens
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway South East Suite 1900
30339, Atlanta
+678 392 3419
http://www.inhibikase.com![Adres Inhibikase Therapeutics, Inc.(IKT)](https://cdn.zonebourse.com/static/address/114338452.png)
Sector
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+10,24% | 10,1 mln. | |
+34,14% | 51,12 mld. | |
-6,54% | 39,4 mld. | |
+34,92% | 38,48 mld. | |
+12,62% | 26,36 mld. | |
-12,11% | 26,22 mld. | |
-13,43% | 20,96 mld. | |
+43,73% | 14,02 mld. | |
+31,81% | 12,49 mld. | |
-4,54% | 11,61 mld. |